A simple non-destructive test of cellular activity (NTCA) for in vitro assessment of cancer cell chemosensitivity/resistance
Language English Country Greece Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
17695522
Knihovny.cz E-resources
- MeSH
- Cell Line MeSH
- Cell Growth Processes drug effects MeSH
- Cisplatin administration & dosage MeSH
- Deoxycytidine analogs & derivatives pharmacology MeSH
- Gemcitabine MeSH
- Humans MeSH
- Mammary Glands, Human cytology drug effects MeSH
- Cell Line, Tumor MeSH
- Breast Neoplasms drug therapy metabolism pathology MeSH
- Antineoplastic Agents pharmacology MeSH
- Antineoplastic Combined Chemotherapy Protocols pharmacology MeSH
- Receptors, Estrogen biosynthesis MeSH
- Reproducibility of Results MeSH
- Drug Screening Assays, Antitumor methods MeSH
- Tamoxifen administration & dosage MeSH
- Tetrazolium Salts MeSH
- Thiazoles MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cisplatin MeSH
- Deoxycytidine MeSH
- Gemcitabine MeSH
- Antineoplastic Agents MeSH
- Receptors, Estrogen MeSH
- Tamoxifen MeSH
- Tetrazolium Salts MeSH
- Thiazoles MeSH
- thiazolyl blue MeSH Browser
Determination of chemosensitivity/chemoresistance is becoming increasingly important for individualization of breast cancer chemotherapy. We developed a simple non-destructive test of cellular activity (NTCA) for assessment of the cytopathic effect of antitumour drugs in vitro. Contrary to routinely used methods (e.g. MTT), besides the comparative evaluation of metabolic activity using pH (given by the medium colour), the NTCA enables the simultaneous assessment of proliferation and morphology of cultured cells (phase-contrast microscopy) at any time during the incubation with cytostatics. Moreover, the regenerative potential of the cells can be examined by cell recovery and growth after drug removal. We provide evidence for the relevance of NTCA in chemosensitivity testing of primary breast cancer cells and breast cancer cell lines for cisplatin, gemcitabine and tamoxifen. NTCA represents a simple addition to the chemosensitivity assessment and could also serve for rapid screening of new antitumour strategies.
